Acumen Pharmaceuticals posts smaller than expected Q3 loss
Acumen Pharmaceuticals posts smaller than expected Q3 loss
Overview
Biopharmaceutical company posted narrower-than-expected Q3 loss from operations and net loss
R&D expenses declined yr/yr, while general and administrative expenses rose slightly
Cash balance expected to support operations into early 2027
Outlook
Company expects topline results from ALTITUDE-AD Phase 2 study in November 2026
Company targets IND filing for EBD program lead candidate in mid-2027
Result Drivers
LOWER TRIAL COSTS - Co said decreased R&D expenses were mainly due to reduced manufacturing, materials, and CRO costs for ALTITUDE-AD trial
EBD PROGRAM SPENDING - Co said increased spending for EBD program partially offset lower ALTITUDE-AD trial costs
Company press release: ID:nGNX27Rcxg
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | Beat | $25.37 mln | $30.32 mln (5 Analysts) |
Q3 Income From Operations | Beat | -$25.81 mln | -$30.68 mln (5 Analysts) |
Q3 Loss Per Basic Share |
| $0.35 |
|
Q3 Operating Expenses |
| $25.81 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $8.00, about 304% above its October 23 closing price of $1.98
Reuters Recommended Reads
Oct 24 - Amgen drug combined with immunotherapy extends survival in lung cancer trial
Oct 23 - Revolution's Rasonque improves survival across subgroups in pancreatic cancer patients
Oct 23 - Bristol Myers discloses patient death in early-stage cell therapy study
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)